PMID- 36434570
OWN - NLM
STAT- MEDLINE
DCOM- 20221129
LR  - 20230320
IS  - 1471-2490 (Electronic)
IS  - 1471-2490 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Nov 25
TI  - Diagnostic performance of an immunoassay based on urine exfoliated cell 
      enrichment nanotechnology for upper tract urothelial carcinoma: a retrospective, 
      monocentric study.
PG  - 194
LID - 10.1186/s12894-022-01122-4 [doi]
LID - 194
AB  - BACKGROUND: Noninvasively urine-based diagnostic modalities for upper urinary 
      tract urothelial carcinoma (UTUC) were still lacking. We evaluated the diagnostic 
      value of our previously developed urine-based assay (UTC assay) in UTUC. METHODS: 
      We retrospectively analyzed 90 patients with suspected UTUC and 40 donors without 
      UTUC. Voided urine specimens were analyzed by UTC assay and fluorescence in situ 
      hybridization (FISH). The performance of UTC assay and FISH was compared among 
      the 60 histologically proven UTUC patients and the 40 donors with benign disease. 
      RESULTS: Of the 60 UTUCs, there were 8 low-grade and 52 high-grade cases. Overall 
      sensitivity for UTC assay and FISH were 85% and 73.3%, respectively (P = 0.116). 
      Specificities for UTC assay and FISH were 92.5% and 95%, respectively (P = ns.). 
      By grade, sensitivities of UTC assay and FISH were 87.5% vs. 37.5% for low-grade 
      (P = 0.119), and 84.6% vs. 78.8% for high- grade UTUC (P = 0.446), respectively. 
      By stage, UTC assay showed significantly higher sensitivity than FISH for 
      detecting non-muscle-invasive UTUC, which were 88.5% vs. 61.5%, respectively 
      (P = 0.025). CONCLUSION: UTC assay has good performance for the non-invasive 
      diagnosis of UTUC. UTC assay may improve the diagnosis and surveillance of 
      low-grade or superficial UTUC.
CI  - (c) 2022. The Author(s).
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Urology, Institute of Urology, Drum Tower Hospital, Medical School 
      of Nanjing University, Nanjing University, 321 Zhongshan Rd, 210008, Nanjing, 
      Jiangsu, China.
FAU - Zhang, Shiwei
AU  - Zhang S
AD  - Department of Urology, Institute of Urology, Drum Tower Hospital, Medical School 
      of Nanjing University, Nanjing University, 321 Zhongshan Rd, 210008, Nanjing, 
      Jiangsu, China.
FAU - Wu, Lang
AU  - Wu L
AD  - PerMed Biomedicine Institute, 201321, Shanghai, China.
FAU - Feng, Baofu
AU  - Feng B
AD  - Department of Urology, Institute of Urology, Drum Tower Hospital, Medical School 
      of Nanjing University, Nanjing University, 321 Zhongshan Rd, 210008, Nanjing, 
      Jiangsu, China.
FAU - Shen, Hongwei
AU  - Shen H
AD  - Department of Urology, Institute of Urology, Drum Tower Hospital, Medical School 
      of Nanjing University, Nanjing University, 321 Zhongshan Rd, 210008, Nanjing, 
      Jiangsu, China.
FAU - Gu, Yuanyuan
AU  - Gu Y
AD  - PerMed Biomedicine Institute, 201321, Shanghai, China.
FAU - Zhang, Qun
AU  - Zhang Q
AD  - PerMed Biomedicine Institute, 201321, Shanghai, China.
FAU - Fang, Feng
AU  - Fang F
AD  - Department of Pharmacology, Nanjing Medical University, 210000, Nanjing, Jiangsu, 
      China.
FAU - Yang, Rong
AU  - Yang R
AD  - Department of Urology, Institute of Urology, Drum Tower Hospital, Medical School 
      of Nanjing University, Nanjing University, 321 Zhongshan Rd, 210008, Nanjing, 
      Jiangsu, China. doctoryr@gmail.com.
FAU - Guo, Hongqian
AU  - Guo H
AD  - Department of Urology, Institute of Urology, Drum Tower Hospital, Medical School 
      of Nanjing University, Nanjing University, 321 Zhongshan Rd, 210008, Nanjing, 
      Jiangsu, China. dr.ghq@nju.edu.cn.
LA  - eng
GR  - 81772727 and 81772710/National Natural Science Foundation of China/
GR  - ZDXKB2016014/The Project of Invigorating Health Care through Science, Technology 
      and Education, Jiangsu Provincial Key Medical Discipline (Laboratory)/
PT  - Journal Article
DEP - 20221125
PL  - England
TA  - BMC Urol
JT  - BMC urology
JID - 100968571
SB  - IM
CIN - Nat Rev Urol. 2023 Jan;20(1):8. PMID: 36477221
MH  - Humans
MH  - *Carcinoma, Transitional Cell/diagnosis/pathology
MH  - *Urinary Bladder Neoplasms/pathology
MH  - Retrospective Studies
MH  - In Situ Hybridization, Fluorescence
MH  - Immunoassay
MH  - Nanotechnology
PMC - PMC9700989
OTO - NOTNLM
OT  - FISH
OT  - Immunocytology
OT  - Upper urinary tract
OT  - Urine
OT  - Urothelial carcinoma
COIS- The authors declare that they have no competing interests.
EDAT- 2022/11/27 06:00
MHDA- 2022/11/30 06:00
PMCR- 2022/11/25
CRDT- 2022/11/26 11:47
PHST- 2022/08/03 00:00 [received]
PHST- 2022/10/12 00:00 [accepted]
PHST- 2022/11/26 11:47 [entrez]
PHST- 2022/11/27 06:00 [pubmed]
PHST- 2022/11/30 06:00 [medline]
PHST- 2022/11/25 00:00 [pmc-release]
AID - 10.1186/s12894-022-01122-4 [pii]
AID - 1122 [pii]
AID - 10.1186/s12894-022-01122-4 [doi]
PST - epublish
SO  - BMC Urol. 2022 Nov 25;22(1):194. doi: 10.1186/s12894-022-01122-4.